Wegovy and Ozempic contain the exact same active ingredient, semaglutide, and are made by the same manufacturer, Novo Nordisk. They work identically in the body. But they are not interchangeable: each is approved for a different medical purpose, sold at different doses, and covered by insurance under different rules.
Same Drug, Different Purpose
Semaglutide belongs to a class of drugs that mimic a natural gut hormone called GLP-1. It slows digestion, reduces appetite, and helps the pancreas release insulin more effectively. Both Wegovy and Ozempic deliver this same molecule through a weekly injection under the skin.
The key difference is what each version is approved to treat. Ozempic is FDA-approved specifically for managing blood sugar in people with type 2 diabetes. Wegovy is FDA-approved for chronic weight management in adults (and children 12 and older) with obesity or who are overweight with at least one weight-related health condition. Wegovy also has a newer approval to reduce the risk of heart attack and stroke in adults with cardiovascular disease who are overweight.
This distinction matters more than it sounds. Ozempic should not be used for weight loss alone, according to clinical guidance from the VA and other health systems. If your primary goal is weight management rather than blood sugar control, Wegovy is the indicated product.
Dosing Differences
Both medications start at the same place: 0.25 mg once a week for the first four weeks, then gradually increase. But they climb to different ceilings. Ozempic’s maintenance doses are lower because the goal is blood sugar management, not maximum weight loss. Wegovy ramps up through several steps over roughly 16 to 20 weeks and can reach a maintenance dose of up to 7.2 mg per week with the newer Wegovy HD formulation, which is substantially higher than the top Ozempic dose.
The higher dose is part of why Wegovy produces more dramatic weight loss in clinical trials. In the landmark STEP 1 trial, participants on the 2.4 mg weekly dose of semaglutide (the original Wegovy maintenance dose) lost an average of 14.9% of their body weight over 68 weeks, compared to just 2.4% in the placebo group. About 86% of people on semaglutide lost at least 5% of their body weight.
The Injection Pens Are Different
Ozempic comes as a multi-use pen, meaning one pen contains several doses. You dial in your prescribed amount each week and use the same pen until it runs out. Wegovy uses single-use prefilled pens: each pen contains one dose, and you throw it away after a single injection. Both are injected in the stomach, thigh, or upper arm once weekly.
Switching Between Them
Because the active ingredient is identical, switching from Ozempic to Wegovy (or vice versa) is medically straightforward but still requires medical supervision. Clinical conversion guidance recommends that patients on Ozempic’s higher doses can transition to Wegovy at a comparable or slightly higher dose, provided they’ve been stable on their current dose for at least four weeks. The first Wegovy injection is typically given seven days after the last Ozempic dose, maintaining the once-weekly schedule without overlap.
Your provider may need to adjust the dose during the transition, especially if you’re moving to Wegovy’s higher weight-management doses and haven’t been on an equivalent amount of semaglutide before.
Insurance and Cost
This is where the “same drug, different label” distinction creates the most real-world frustration. Insurance coverage depends almost entirely on which condition you’re being treated for.
Medicare covers Ozempic when prescribed for type 2 diabetes. However, a 2003 federal rule prohibits Medicare from covering drugs used solely for chronic weight management, which means Medicare historically has not covered Wegovy for weight loss. That changed partially with Wegovy’s cardiovascular approval: Medicare prescription plans may now cover Wegovy for adults with heart disease who are overweight, since the purpose is reducing cardiovascular risk rather than weight loss alone.
Private insurance varies widely. Many plans cover Ozempic for diabetes with prior authorization. Coverage for Wegovy is less consistent. Some insurers cover it for weight management, others exclude it, and many require documentation of failed diet and exercise programs, a specific BMI threshold, or other criteria before approving it. The out-of-pocket cost without insurance for either drug can run over $1,000 per month, which is why the coverage distinction between the two labels carries significant financial weight.
Side Effects Are the Same
Because both drugs deliver the same molecule, the side effect profile is essentially identical. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach pain. These tend to be worst during the dose-escalation phase, when your body is adjusting to increasing amounts of semaglutide, and often improve once you reach a stable maintenance dose.
Higher doses generally mean a greater chance of side effects, so people on Wegovy’s top doses may experience more GI discomfort than those on lower Ozempic doses. The gradual dose-titration schedule for both products exists specifically to minimize this. Starting low and increasing every four weeks gives your body time to adapt.
Which One Is Right for You
The choice between Wegovy and Ozempic isn’t really about which drug is “better.” It’s about your diagnosis. If you have type 2 diabetes, Ozempic is the standard option (and weight loss is a welcome secondary benefit). If your primary need is weight management and you meet the criteria, Wegovy is the appropriate product. Some people with type 2 diabetes and obesity may benefit from Wegovy’s higher doses, but that decision involves weighing insurance coverage, cost, and clinical goals with a prescriber.
The bottom line: Wegovy and Ozempic are the same molecule in different packaging, approved at different doses, for different conditions, with different insurance pathways. They are not interchangeable at the pharmacy, but they work the same way in your body.